OXFORD PHARMAGENESIS HOLDINGS LIMITED
OXFORD PHARMAGENESIS HOLDINGS LIMITED is a Private limited company (Ltd.) registered in United Kingdom under 08242591, and its current status with Companies House is active. The company was incorporated on 5 October 2012 and lists its registered address as Abingdon, United Kingdom. 5 shareholders are on record for OXFORD PHARMAGENESIS HOLDINGS LIMITED, including at least one natural person recorded as a direct holder; the filing carries no beneficial-ownership flag, so that holder is noted here as a recorded shareholder rather than a confirmed ultimate beneficial owner (UBO). This profile is sourced directly from Companies House and was last updated on 9 October 2026.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Five shareholders are currently on record for OXFORD PHARMAGENESIS HOLDINGS LIMITED, held on the Confirmation Statement (CS01), filed under the Companies Act 2006.
The largest of these is HELD IN TREASURY, holding 49.7% — the largest recorded stake — followed by RICHARD WHITE at 13.8%; the remaining 3 shareholders shown hold smaller stakes.
The register reports 19 shareholders in total, though only the top 5 by holding are shown in this view.
2 shareholders shown are companies, so the ownership chain continues above this level for those holdings; the other 3 are recorded as direct individual holders, though the record carries no UBO/PSC flag confirming beneficial-owner status.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| HELD IN TREASURY | 49.7% | Companies House | |
| RICHARD WHITE | 13.8% | Companies House | |
| CHRISTOPHER CHARLES WINCHESTER | 13.8% | Companies House | |
| CHRISTOPHER CHARLES WINCHESTER | 13.8% | Companies House | |
| HELD IN TREASURY | 3.7% | Companies House |
Officers
5
Three of the 5 officer records shown for OXFORD PHARMAGENESIS HOLDINGS LIMITED are current appointments, filed with Companies House. Michael Becker (appointed 2026-06-24), Aaron Hersh Goldstein (appointed 2026-06-24) and Leerom Segal (appointed 2026-06-24) all serve as Director. The remaining 2 records shown (Richard White and James Tustian) are former appointments that have since been resigned.
The register reports 12 officers in total, including past appointments, though only the 5 most relevant records are shown here.
Management authority at OXFORD PHARMAGENESIS HOLDINGS LIMITED sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.
The source filing doesn't specify representation authority — whether officers can act individually or must sign jointly to bind the company — so that detail isn't available here.
Group Structure
OXFORD PHARMAGENESIS HOLDINGS LIMITED has no recorded parent company — it sits at the top of its own group structure, with 1 subsidiary recorded beneath it across 1 jurisdiction. Each of these downward relationships is derived rather than filed: resolved by matching entities across the registry network, not stated directly in a single document.
Those 1 subsidiary spans United Kingdom jurisdiction, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear. One of the 1 go a level deeper still, with its own further subsidiaries recorded beneath it — additional ownership layers this view doesn't expand.
OXFORD PHARMAGENESIS HOLDINGS LIMITED
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
Who owns OXFORD PHARMAGENESIS HOLDINGS LIMITED?
Five shareholders are currently on record for OXFORD PHARMAGENESIS HOLDINGS LIMITED, held on the Confirmation Statement (CS01), filed under the Companies Act 2006. The largest of these is HELD IN TREASURY, holding 49.7% — the largest recorded stake — followed by RICHARD WHITE at 13.8%; the remaining 3 shareholders shown hold smaller stakes. 2 shareholders shown are companies, so the ownership chain continues above this level for those holdings; the other 3 are recorded as direct individual holders, though the record carries no UBO/PSC flag confirming beneficial-owner status.
Who is OXFORD PHARMAGENESIS HOLDINGS LIMITED's UBO (Ultimate Beneficial Owner)?
At least one shareholder recorded for OXFORD PHARMAGENESIS HOLDINGS LIMITED is a natural person. The record carries no dedicated UBO/PSC flag, so that holder is stated here as a recorded shareholder rather than a confirmed Ultimate Beneficial Owner (UBO).
How many shareholders does OXFORD PHARMAGENESIS HOLDINGS LIMITED have on record?
5 shareholders are shown on record for OXFORD PHARMAGENESIS HOLDINGS LIMITED. The register reports 19 in total; only the top 5 by holding are shown here.
What is OXFORD PHARMAGENESIS HOLDINGS LIMITED's company registration number?
OXFORD PHARMAGENESIS HOLDINGS LIMITED's registration number is 08242591, filed with Companies House in United Kingdom. Its current status on the register is active.
Is OXFORD PHARMAGENESIS HOLDINGS LIMITED still an active company?
OXFORD PHARMAGENESIS HOLDINGS LIMITED's status on Companies House is listed as active.
When was OXFORD PHARMAGENESIS HOLDINGS LIMITED incorporated?
OXFORD PHARMAGENESIS HOLDINGS LIMITED was incorporated on 5 October 2012, according to Companies House.
What is OXFORD PHARMAGENESIS HOLDINGS LIMITED's registered address?
The registered address on file for OXFORD PHARMAGENESIS HOLDINGS LIMITED is Abingdon, United Kingdom.
What legal structure is OXFORD PHARMAGENESIS HOLDINGS LIMITED registered as?
OXFORD PHARMAGENESIS HOLDINGS LIMITED is registered as a Private limited company (Ltd.) in United Kingdom.
Who are the officers/directors of OXFORD PHARMAGENESIS HOLDINGS LIMITED?
Three of the 5 officer records shown for OXFORD PHARMAGENESIS HOLDINGS LIMITED are current appointments, filed with Companies House. Michael Becker (appointed 2026-06-24), Aaron Hersh Goldstein (appointed 2026-06-24) and Leerom Segal (appointed 2026-06-24) all serve as Director. The remaining 2 records shown (Richard White and James Tustian) are former appointments that have since been resigned. Management authority at OXFORD PHARMAGENESIS HOLDINGS LIMITED sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.
Does OXFORD PHARMAGENESIS HOLDINGS LIMITED have a parent company or subsidiaries?
OXFORD PHARMAGENESIS HOLDINGS LIMITED has no recorded parent company — it sits at the top of its own group structure, with 1 subsidiary recorded beneath it across 1 jurisdiction. Those 1 subsidiary spans United Kingdom jurisdiction, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear. One of the 1 go a level deeper still, with its own further subsidiaries recorded beneath it — additional ownership layers this view doesn't expand.
Can Zavia monitor changes to OXFORD PHARMAGENESIS HOLDINGS LIMITED's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to OXFORD PHARMAGENESIS HOLDINGS LIMITED's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access OXFORD PHARMAGENESIS HOLDINGS LIMITED's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like OXFORD PHARMAGENESIS HOLDINGS LIMITED's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 9 October 2026.